Preclinical Model

Its value depends on how well the selected system reproduces the human biological feature being studied. Researchers compare disease-related responses, pharmacological activity, or toxicity under controlled conditions, then assess whether the findings consistently support a plausible benefit and acceptable risk. This evidence helps determine whether an intervention merits clinical investigation, while recognizing that translation to humans remains uncertain.

Different systems reproduce different aspects of human biology. Cultured cells, organoids, tissues, and laboratory animals can therefore provide distinct types of evidence about disease progression, treatment effects, or safety. Selecting a model according to the question allows researchers to measure relevant responses rather than treating one system as a complete representation of human physiology.

No experimental system fully represents human physiology, so a favorable result does not establish that an intervention will be effective or safe in patients. Findings are interpreted as evidence about selected biological features, measured outcomes, and potential risks. This limitation matters when researchers design later studies and decide how strongly the results support clinical evaluation.

Depending on the study purpose, researchers may examine toxicity, pharmacological activity, disease progression, or biological responses to an intervention. These measurements provide different forms of evidence: toxicity can reveal potential harm, pharmacological activity can indicate treatment effects, and disease-progression data can show how the condition changes under controlled experimental conditions.

Researchers apply them to investigate whether a biological target is relevant to disease and whether influencing that target produces a measurable response. The same systems can support early assessment of pharmacological activity and toxicity. Together, these results help prioritize interventions, identify potential risks, and determine whether development should proceed toward studies in humans.

Researchers first select an experimental system suited to the disease, biological response, or intervention being examined. They then measure relevant outcomes, including activity, toxicity, or disease progression, under controlled conditions. The resulting evidence informs study design and treatment optimization, and helps determine whether the intervention has sufficient potential benefit and manageable risk for clinical investigation.